What is Zevra Therapeutics, Inc.'s market cap?

Zevra Therapeutics, Inc. (ZVRA) has a market capitalization of $574.0M and trades on NASDAQ.

What is Zevra Therapeutics, Inc.'s revenue and profitability?

Zevra Therapeutics, Inc. generated $122.3M in trailing twelve-month revenue with net income of $124.2M, representing a net margin of 101.6%. Gross margin stands at 86.1%, with free cash flow of -$22.3M. These figures are based on the Q1 2026 filing.

Who are Zevra Therapeutics, Inc.'s competitors?

Zevra Therapeutics, Inc.'s key competitors include Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, Fulcrum Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Zevra Therapeutics, Inc. partner with?

Zevra Therapeutics, Inc.'s notable partners include European Medicines Agency, U.S. Food and Drug Administration.

What subsidiaries does Zevra Therapeutics, Inc. have?

Zevra Therapeutics, Inc.'s subsidiaries include Acer Therapeutics, Inc., Orphazyme A/S.

Where is Zevra Therapeutics, Inc. headquartered?

Zevra Therapeutics, Inc. is headquartered in United States of America and employs approximately 69 people. It has been publicly traded since 2015.

Zevra Therapeutics, Inc.

ZVRA

Zevra Therapeutics is a commercial-stage biotechnology company dedicated to developing and commercializing transformative therapies for rare diseases with significant unmet medical needs.

Market cap

$574.01M-4.5%

Revenue$122.3M+201%

Net income$124.2M+235%

Free cash flow-$22.3M+68.0%

EPS (diluted)$1.99+204%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$36.2MBeat by $4.3M EPS$0.18Beat by $0.12

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$33.9M

EPS estimate$0.08

Financials

Q1 2026

Income statement

See full

Revenue$36.2M+77.5%

Gross profit$34.3M+80.1%

Operating income$52.1M+1,073%

Net income$37.9M+1,323%

EPS (diluted)$0.60+1,100%

Balance sheet

See full

Cash & equivalents$95.6M+156%

Total debt$1.1M-98.1%

Total equity$205.8M+402%

Total assets$278.6M+61.3%

Cash flow

See full

Operating cash flow$6.1M+175%

CapEx$35.0K-64.6%

Free cash flow$6.1M+173%

Valuation & ratios

Valuation

See full

Market cap$574.01M-4.5%

Enterprise value$479.56M-20.8%

P/E4.6×-219×

P/S4.7×-4.8×

Profitability

See full

Gross margin86.1%+7.2pp

Net margin101.6%+60.1pp

Returns & leverage

See full

Return on equity100.7%+60.3pp

Debt / equity0×-1.5×

Current ratio4.9×+1.9×

Segments

By product

See full

MIPLYFFA$24.6M+43.9%

OLPRUVA$300.0K+200%

By segment

See full

Reportable Segment$36.2M+77.5%

Competitors

By market cap

Arrowhead Research$12.0B+439%

BioMarin Pharmaceuticals$11.6B+4.5%

Relay Therapeutics, Inc.$4.1B+540%

Ultragenyx Pharmaceutical$2.6B+1.5%

XER

Xeris Biopharma Holdings, Inc.$1.4B+74.6%

Zevra Therapeutics, Inc.$574.0M-2.9%

Fulcrum Therapeutics, Inc.$248.5M-41.0%

Polaryx Therapeutics, Inc. $97.7M—

By revenue growth

Zevra Therapeutics, Inc.+201%

XER

Xeris Biopharma Holdings, Inc.+41.5%

Relay Therapeutics, Inc.+39.0%

Arrowhead Research+14.1%

Ultragenyx Pharmaceutical+13.5%

BioMarin Pharmaceuticals+9.9%

By net margin

Zevra Therapeutics, Inc.101.58%+328pp

BioMarin Pharmaceuticals16.82%+1.0pp

XER

Xeris Biopharma Holdings, Inc.3.81%+24.1pp

Arrowhead Research-48.38%-22.0pp

Ultragenyx Pharmaceutical-90.92%+2.2pp

Relay Therapeutics, Inc.-2,554.14%+1,787pp

Profile

Zevra Therapeutics is a commercial-stage biotechnology company dedicated to developing and commercializing transformative therapies for rare diseases with significant unmet medical needs. The company leverages a specialized infrastructure to advance late-stage clinical assets and manage a portfolio of marketed products for neurodegenerative and metabolic disorders. Its strategy combines internal development with inorganic growth through the acquisition of orphan drug assets.

Competitive position

A specialized rare-disease player with a commercial-stage foundation and a late-stage pipeline, utilizing Priority Review Vouchers and orphan designations to maintain a competitive edge.

GeographiesUnited States, European Union

Customer segmentsRare Disease Patients, Specialty Healthcare Providers

Business modelProduct-based, Inorganic Growth, Research and Development

SuppliersContract Manufacturing Organizations, Clinical Research Organizations, Raw Material Suppliers

CustomersSpecialty Distributors, Patients, Healthcare Systems, Payors

CountryUnited States of America

Listed2015

Employees69.0

CEONeil F. McFarlane

SectorHealthcare

IndustryBiotechnology

Websitezevra.com

FilingsSEC EDGAR

Ask your AI about Zevra Therapeutics, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s market cap?: Zevra Therapeutics, Inc. (ZVRA) has a market capitalization of $574.0M and trades on NASDAQ.
What is Zevra Therapeutics, Inc.'s revenue and profitability?: Zevra Therapeutics, Inc. generated $122.3M in trailing twelve-month revenue with net income of $124.2M, representing a net margin of 101.6%. Gross margin stands at 86.1%, with free cash flow of -$22.3M. These figures are based on the Q1 2026 filing.
Who are Zevra Therapeutics, Inc.'s competitors?: Zevra Therapeutics, Inc.'s key competitors include Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, Fulcrum Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Zevra Therapeutics, Inc. partner with?: Zevra Therapeutics, Inc.'s notable partners include European Medicines Agency, U.S. Food and Drug Administration.
What subsidiaries does Zevra Therapeutics, Inc. have?: Zevra Therapeutics, Inc.'s subsidiaries include Acer Therapeutics, Inc., Orphazyme A/S.
Where is Zevra Therapeutics, Inc. headquartered?: Zevra Therapeutics, Inc. is headquartered in United States of America and employs approximately 69 people. It has been publicly traded since 2015.